New insider activity at Blueprint Medicines ( (BPMC) ) has taken place on March 18, 2025.
Director Jeffrey Albers has recently sold 5,766 shares of Blueprint Medicines stock, amounting to a total transaction value of $512,020.
Recent Updates on BPMC stock
In the last 24 hours, Blueprint Medicines has seen significant analyst activity with Wolfe Research, Jefferies, and Scotiabank initiating coverage with positive ratings. Wolfe Research is optimistic about the company’s Ayvakit earnings, predicting a higher prevalence of patients than the company estimates, and is closely watching upcoming data from Cogent’s bezuclastinib. Jefferies finds the stock attractive due to a recent pullback and anticipates a rebound as the company executes on Ayvakit’s launch, driven by increased awareness and utilization. Scotiabank highlights the potential of Blueprint’s systemic mastocytosis franchise and the promising prospects of BLU-808, which could significantly drive share value. These factors contribute to the positive outlook and price target adjustments for Blueprint Medicines.
More about Blueprint Medicines
YTD Price Performance: 2.73%
Average Trading Volume: 953,146
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $5.72B